Immune Checkpoint Inhibitors for Urologic Cancers
A special issue of Current Oncology (ISSN 1718-7729).
Deadline for manuscript submissions: closed (1 May 2024) | Viewed by 210
Special Issue Editor
Interests: identification of biomarkers for prostate; kidney and bladder cancer; neuroendocrine prostate cancer; PSMA theranostics; upper tract urothelial carcinoma; treatment-resistant urothelial carcinoma; genomics and immunogenomics for urological cancers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to invite you to submit a manuscript to the Special Issue, “Immune Checkpoint Inhibitors for Urologic Cancers”. Urologic malignancies, including prostate, urothelial, kidney and testicular carcinomas, are increasingly diagnosed in Western countries. Despite advances in definitive therapies, metastatic disease remains lethal. The addition of immune checkpoint inhibitors in the armamentarium of current therapeutic modalities in urothelial and kidney cancers has fueled significant research to elucidate the genomic and immunogenomic context of urologic cancers, biomarkers predictive of clinical outcomes and novel therapeutic combinations.
This Special Issue of Current Oncology welcomes original research articles and reviews related to all aspects of immune checkpoint inhibitor use in urologic cancers.
We are looking forward to receiving your contributions.
You may choose our Joint Special Issue in Cancers.
Sincerely,
Dr. Panagiotis Vlachostergios
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- identification of biomarkers for prostate
- kidney and bladder cancer
- neuroendocrine prostate cancer
- PSMA theranostics
- upper tract urothelial carcinoma
- treatment-resistant urothelial carcinoma
- genomics and immunogenomics for urological cancers
